Wall Street brokerages expect Synlogic Inc (NASDAQ:SYBX) to announce sales of $960,000.00 for the current fiscal quarter, according to Zacks. Five analysts have made estimates for Synlogic’s earnings. The highest sales estimate is $3.13 million and the lowest is $300,000.00. Synlogic posted sales of $250,000.00 in the same quarter last year, which suggests a positive year over year growth rate of 284%. The business is expected to announce its next quarterly earnings report on Wednesday, August 14th.

According to Zacks, analysts expect that Synlogic will report full year sales of $1.97 million for the current fiscal year, with estimates ranging from $300,000.00 to $4.71 million. For the next fiscal year, analysts anticipate that the firm will post sales of $1.55 million, with estimates ranging from $1.30 million to $2.00 million. Zacks’ sales averages are an average based on a survey of research analysts that that provide coverage for Synlogic.

Synlogic (NASDAQ:SYBX) last released its quarterly earnings results on Thursday, May 9th. The biotechnology company reported ($0.51) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.54) by $0.03. Synlogic had a negative return on equity of 38.93% and a negative net margin of 2,005.43%. The business had revenue of $0.34 million for the quarter, compared to the consensus estimate of $0.42 million.

A number of research analysts have recently issued reports on the company. HC Wainwright reaffirmed a “buy” rating and set a $20.00 price objective on shares of Synlogic in a research note on Monday, June 24th. Wedbush reissued an “outperform” rating and issued a $20.00 target price on shares of Synlogic in a research note on Wednesday, June 12th. Piper Jaffray Companies raised their target price on Synlogic from $15.00 to $16.00 and gave the stock an “overweight” rating in a research note on Wednesday, June 12th. Zacks Investment Research raised Synlogic from a “hold” rating to a “buy” rating and set a $8.75 target price on the stock in a research note on Wednesday, May 15th. Finally, Jefferies Financial Group started coverage on Synlogic in a research note on Tuesday, April 30th. They issued a “buy” rating and a $18.00 target price on the stock. One equities research analyst has rated the stock with a hold rating and nine have issued a buy rating to the company’s stock. The company presently has an average rating of “Buy” and an average target price of $18.75.

A number of institutional investors have recently bought and sold shares of the business. Northern Trust Corp lifted its holdings in shares of Synlogic by 1.2% during the fourth quarter. Northern Trust Corp now owns 167,135 shares of the biotechnology company’s stock valued at $1,172,000 after purchasing an additional 2,005 shares during the last quarter. Alps Advisors Inc. lifted its holdings in shares of Synlogic by 4.5% during the first quarter. Alps Advisors Inc. now owns 61,466 shares of the biotechnology company’s stock valued at $467,000 after purchasing an additional 2,658 shares during the last quarter. Bank of New York Mellon Corp lifted its holdings in shares of Synlogic by 12.1% during the fourth quarter. Bank of New York Mellon Corp now owns 56,774 shares of the biotechnology company’s stock valued at $398,000 after purchasing an additional 6,129 shares during the last quarter. Rhumbline Advisers lifted its holdings in shares of Synlogic by 45.7% during the fourth quarter. Rhumbline Advisers now owns 21,753 shares of the biotechnology company’s stock valued at $152,000 after purchasing an additional 6,820 shares during the last quarter. Finally, Bank of Montreal Can lifted its holdings in shares of Synlogic by 5,743.1% during the first quarter. Bank of Montreal Can now owns 12,738 shares of the biotechnology company’s stock valued at $97,000 after purchasing an additional 12,520 shares during the last quarter. 81.89% of the stock is currently owned by institutional investors and hedge funds.

Shares of NASDAQ:SYBX traded down $0.33 on Wednesday, reaching $8.67. 80,314 shares of the company traded hands, compared to its average volume of 97,760. The business has a 50-day simple moving average of $8.26. Synlogic has a 52 week low of $5.75 and a 52 week high of $14.59. The stock has a market capitalization of $229.01 million, a PE ratio of -4.27 and a beta of 2.43. The company has a debt-to-equity ratio of 0.20, a current ratio of 11.53 and a quick ratio of 11.53.

Synlogic Company Profile

Synlogic, Inc a clinical-stage biopharmaceutical company, focuses on the discovery and development of synthetic biotic medicines to treat metabolic, inflammatory, and cancer diseases in the United States. Its lead therapeutic programs include SYNB1020, an oral therapy for the treatment of hyperammonemia, which includes patients with liver diseases, such as hepatic encephalopathy, as well as patients with urea cycle disorders; and SYNB1618, an oral therapy that is in Phase I/IIa clinical trial to treat phenylketonuria.

Further Reading: Why is cost of goods sold important?

Get a free copy of the Zacks research report on Synlogic (SYBX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Synlogic (NASDAQ:SYBX)

Receive News & Ratings for Synlogic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Synlogic and related companies with MarketBeat.com's FREE daily email newsletter.